Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	-	31/12/2017

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-1.48%	-8.28%	-20.60%	-68.71%	22.75M
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+16.49%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+579.98%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+81.78%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.07%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+54.40%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+124.45%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.47%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+29.70%	12.77B
Average	+1.76%	+4.86%	+73.91%	+94.18%	26.49B
Weighted average by Cap.	+2.54%	+6.10%	+105.12%	+138.65%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	SEK 1.064	-1.48%	1,844,666
06/08/26	SEK 1.080	+5.06%	1,992,704
05/08/26	SEK 1.028	-1.34%	2,087,137
04/08/26	SEK 1.042	-4.93%	4,290,961
03/08/26	SEK 1.096	-5.52%	5,527,250

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 07/08/2026 BST			5-day change	1st Jan Change
1.064 ^SEK	-1.48%		-8.28%	+28.35%

Market Cap	216M 22.75M 19.68M 18.38M 16.86M 31.71M 2.17B 32.21M 84.63M 1.09B 85.43M 83.56M 3.59B	P/E 2026 *	-3.94x	P/E 2027 *	-2.8x
Enterprise Value	200M 21.06M 18.22M 17.01M 15.61M 29.36M 2B 29.82M 78.35M 1B 79.09M 77.36M 3.32B	EV / Sales 2026 *	6.37x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	-1.48%
1 week	-8.28%
Current month	-8.28%
1 month	+3.10%
3 months	+165.34%
6 months	+50.07%
Current year	+28.35%

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.98	1.23
1 month	0.61	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.31M 2.86M 2.67M 2.45M 4.61M 315M 4.68M 12.3M 158M 12.42M 12.15M 522M	-
Net income	-3.2M -338K -292K -273K -250K -471K -32.13M -478K -1.26M -16.11M -1.27M -1.24M -53.25M	-50.35M -5.31M -4.6M -4.29M -3.94M -7.4M -506M -7.52M -19.76M -253M -19.95M -19.51M -838M
Net Debt	-16M -1.69M -1.46M -1.36M -1.25M -2.35M -161M -2.39M -6.28M -80.53M -6.34M -6.2M -266M	-19M -2M -1.73M -1.62M -1.49M -2.79M -191M -2.84M -7.46M -95.63M -7.53M -7.36M -316M